BIVI Biovie Inc
Price (delayed)
$0.9523
Market cap
$17.57M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.46
Enterprise value
-$6.45M
BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of
Highlights
BIVI's debt has shrunk by 96% YoY and by 90% QoQ
The EPS has soared by 70% YoY and by 33% from the previous quarter
Key stats
What are the main financial stats of BIVI
Market
Valuations
Earnings
Shares outstanding
18.45M
Market cap
$17.57M
Enterprise value
-$6.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.71
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$23.94M
Net income
-$24.27M
EBIT
-$22.88M
EBITDA
-$22.57M
Free cash flow
-$22.02M
Per share
Balance sheet
Liquidity
EPS
-$3.46
EPS diluted
-$3.46
Free cash flow per share
-$1.4
Book value per share
$1.35
Revenue per share
$0
TBVPS
$1.59
Total assets
$25.69M
Total liabilities
$1.77M
Debt
$382,026
Equity
$23.92M
Working capital
$23.22M
Debt to equity
0.02
Current ratio
16.94
Quick ratio
16.75
Net debt/EBITDA
1.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-98.3%
Return on equity
-141%
Return on invested capital
N/A
Return on capital employed
-94.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIVI stock price
How has the Biovie stock price performed over time
Intraday
13.37%
1 week
-8.87%
1 month
-28.4%
1 year
-81.86%
YTD
-52.39%
QTD
-2.83%
Financial performance
How have Biovie's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.94M
Net income
-$24.27M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 46% YoY and by 6% QoQ
The net income is up by 44% year-on-year and by 5% since the previous quarter
Growth
What is Biovie's growth rate over time
Valuation
What is Biovie stock price valuation
P/E
N/A
P/B
0.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 70% YoY and by 33% from the previous quarter
The price to book (P/B) is 94% lower than the 5-year quarterly average of 11.2 and 48% lower than the last 4 quarters average of 1.2
BIVI's equity has surged by 70% since the previous quarter
Efficiency
How efficient is Biovie business performance
BIVI's ROE has soared by 58% YoY and by 26% QoQ
The company's return on assets rose by 29% YoY and by 8% QoQ
Dividends
What is BIVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIVI.
Financial health
How did Biovie financials performed over time
BIVI's total liabilities has dropped by 87% year-on-year and by 75% since the previous quarter
Biovie's total assets has increased by 21% from the previous quarter and by 20% YoY
BIVI's debt is 98% lower than its equity
BIVI's debt to equity has plunged by 99% YoY and by 92% from the previous quarter
BIVI's debt has shrunk by 96% YoY and by 90% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.